INOTREM
Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005071/en/
As part of this program, Inotrem receives additional 45 million euros in public funding under the "Capacity Building" Call for Expression of Interest, operated on behalf of the French government by Bpifrance, the French national investment bank, as part of the Programme d’investissements d’avenir (PIA) and the France Recovery Plan, bringing French state support for the project to a total of 52,5 million euros. This public funding will support Inotrem’s clinical program including the phase 2/3 study “ESSENTIAL” which aims to demonstrate the efficacy and safety of nangibotide in treating patients in respiratory distress with severe forms of COVID-19.
The primary endpoint is evaluation of the impact of nangibotide on the progression of disease in patients receiving ventilatory support due to COVID-19 as well as on the severity of the respiratory failure, duration of mechanical ventilation, length of stay in intensive care and mortality. In “ESSENTIAL”, a Phase 2/3 clinical program, up to 730 patients will be enrolled initially in France and Belgium and, possibly in other European countries. Pre-defined interim analyses will be conducted by an independent Data Monitoring Board to test futility and to allow for the study design to be adapted as necessary. “ESSNTIAL” is the continuation of a 60 patients phase 2a evaluating the safety and efficacy of nangibotide in patients suffering from severe COVID-19. In July 2020, the CoviTREM-1 consortium, which includes the Nancy and Limoges university hospitals and Inotrem, obtained public funding of 7,5 million euros under the “PSPC-COVID” call for projects, operated on behalf of the French government by Bpifrance
New pre-clinical studies with nangibotide have demonstrated that the administration of nangibotide in murine models infected with SARS-CoV-2 was associated with a decrease in inflammatory mediators and an improvement of clinical signs, in particular respiratory function, and survival. Inotrem also confirmed in 3 different and independent cohorts that sTREM-1, a marker of the activation of the TREM-1 biological pathway, is associated with both severity and mortality in critically ill COVID-19 patients.
Leveraging the results of these preclinical studies and the implications for the role of the TREM-1 pathway in COVID-19, Inotrem has filed additional patents to cover nangibotide use in severe forms of COVID-19 as well as the use of sTREM-1 as a biomarker and companion diagnostic. This significantly strengthens Inotrem’s already broad patent estate.
Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder said :“We are eager to pursue the development of nangibotide in these severe forms of COVID-19. Nangibotide is a TREM-1 inhibitor which has already demonstrated a trend towards efficacy in septic shock patients and has the potential to modulate the dysregulated immune response in critically ill COVID-19 patients. With this large clinical study, we can demonstrate efficacy for nangibotide in a further indication with the goals of reducing the duration of hospitalization and mortality.”
Sven Zimmerman, CEO of Inotrem, also declared : “The size of the financial support awarded to us as part of the French government’s initiative against COVID-19 is a testimony to the relevance of targeting the TREM-1 pathway with nangibotide in these severely ill patients. We are delighted by the confidence placed in our technology and our team. Everyone at Inotrem is fully committed to deliver on this ambitious program alongside nangibotide’s ongoing Phase 2b trial in septic shock patients.”
About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.
About ESSENTIAL study:
The Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients with ventiLatory support, is a randomized, double-blind, placebo-controlled confirmatory study with adaptive features that will be performed in Europe. This is a pivotal study and it is expected that based on its results, nangibotide could be registered in this indication. The first part of the study (i.e.: 60 patients) has been already finalized and assessed by an independent data monitoring committee with excellent safety results. The study will recruit up to 730 patients in up to 40 sites. Several interim and futility analyses are foreseen as part of the adaptive design of the study.
About Bpifrance
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra-financial services (training, consultancy.). to help entrepreneurs meet their challenges (innovation, export…).
For more information, please visit: www.bpifrance.fr
and presse.bpifrance.fr
Follow us on Twitter: @Bpifrance - @BpifrancePresse
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UMA Launches from Europe to Shape the Global Future of Physical AI1.12.2025 23:52:00 CET | Press release
UMA (Universal Mechanical Assistant), a new robotics intelligence company founded by former leaders from Tesla, Google DeepMind, Nvidia and Hugging Face, launches today with a clear goal: to bring advanced AI into the physical world and build humanoid robots ready for real work, in real environments, at scale. UMA’s founders were instrumental in shaping the last decade of breakthroughs in deep learning, robotics and open-source AI. They are convinced that the next era of artificial intelligence won’t unfold on screens, it will happen in warehouses, hospitals, labs, factories and homes, where machines must face friction, unpredictability and human complexity. UMA is built for this transition: from digital intelligence to physical autonomy. AI Is Moving Off the Screen and into the World The past ten years gave rise to generative models, multimodal systems and language-based intelligence. The next decade will be defined by robotics, powered by an AI that can see, move, manipulate and make
FlightSafety International Appoints Eric Hinson as Chief Executive Officer1.12.2025 23:00:00 CET | Press release
FlightSafety International Inc. today announced the appointment of Eric Hinson as chief executive officer, effective immediately. Hinson will succeed former president Barbara Telek who recently announced her retirement. Hinson’s appointment marks a return to FlightSafety. He served as an executive vice president from 2009 to 2012 before leaving to be the president and CEO of Simcom International, Inc. Hinson started his aviation career as a naval aviator flying tactical aircraft in training, fleet, and operational test squadrons. Today, he is an active ATP-rated pilot with more than 5,000 total flight hours. He brings a unique operational perspective to the position—one that blends executive leadership with firsthand experience. In addition to FlightSafety and Simcom, Hinson has served in a variety of senior leadership positions at leading aviation companies, including Honeywell, Gulfstream, and Piaggio Aerospace. He also served as a board member of the General Aviation Manufacturer As
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 16:13:00 CET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
Rimini Street Announces Additional Stock Repurchase Transactions1.12.2025 15:00:00 CET | Press release
Company will share its vision, strategy, sales and execution model, financial model and guidance at its Investor Day event on December 3, 2025 Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201195169/en/ Rimini Street Announces Additional Stock Repurchase Transactions Share Repurchases The Company repurchased a total of 975,000 shares of common stock to date in the fourth fiscal quarter of 2025, for approximately $3.8 million with an average per share purchase price of $3.92, reducing outstanding shares by approximately 1.1%1. The Company has now completed and announced $13.3 million in common stock repurchases under its $50 million Common Stock Repurchase Plan that was app
MVNO Europe - Europe's Competitiveness Depends on a Truly Open Telecoms Market, Not on Increased Concentration That Benefits a Handful of Mobile Operators1.12.2025 14:37:00 CET | Press release
This is the warning that MVNO Europe – through its President Jacques Bonifay – has issued to the European Commission in an open letter to Ursula von der Leyen and Vice-President Henna Virkkunen. As discussions on the Digital Networks Act (DNA) enter their decisive phase, the association, which brings together alternative mobile operators in Europe, points out that the EU's digital ambition can only be achieved if competition remains a structuring principle, not an adjustment variable. While some players are calling for "necessary" consolidation in the sector, MVNO Europe warns against a simplistic and economically dangerous vision. "Reducing the number of operators has never guaranteed innovation, access for European industries, or fair conditions for new digital services. On the contrary, the historical driver of European competitiveness has always been the diversity of players, models, technologies and services," says Jacques Bonifay, President of MVNO Europe and CEO of Transatel. Re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom